Macrophage Migration Inhibitory Factor and microRNA-451a in Response to Mindfulness-based Therapy or Treatment as Usual in Patients with Depression, Anxiety, or Stress and Adjustment Disorders

Xiao Wang, MD, PhD; Kristina Sundquist, MD, PhD; Karolina Palmér, MSc; Anna Hedelius, BSc; A. A. Memon, MD, PhD; Jan Sundquist, MD, PhD

Center for Primary Health Care Research, Lund University/Region Skåne, Sweden.

Correspondence: Xiao Wang, PhD, Center for Primary Health Care Research, Skåne University Hospital, 205 02 Malmö, Sweden (xiao.wang@med.lu.se).

Abstract

Background: Macrophage migration inhibitory factor is a proinflammatory cytokine that has been associated with various psychiatric disorders. MicroRNA-451a can directly target macrophage migration inhibitory factor and downregulate its expression in cells. However, the role of macrophage migration inhibitory factor and microRNA-451a in psychiatric patients treated with psychotherapeutic interventions is unknown. In this study, our aim was to investigate levels of macrophage migration inhibitory factor and its regulating microRNA-451a in patients with depression, anxiety, or stress and adjustment disorders who underwent mindfulness-based therapy or treatment as usual.

Methods: A total of 168 patients with psychiatric disorders were included from a randomized controlled trial that compared mindfulness-based therapy with treatment as usual. Plasma levels of macrophage migration inhibitory factor and microRNA-451a were measured at baseline and after the 8-week follow-up using Luminex assay and qPCR.

Results: Macrophage migration inhibitory factor levels decreased significantly in patients posttreatment, whereas microRNA-451a levels showed a nonsignificant change. Macrophage migration inhibitory factor levels were inversely associated with microRNA-451a expression levels at baseline (β = −0.04, P = .008). The change in macrophage migration inhibitory factor levels (follow-up levels minus baseline levels) was associated with the change in microRNA-451a (follow-up levels minus baseline levels) (β = −0.06, P < .0001). The change in either macrophage migration inhibitory factor or microRNA-451a was not associated with improvement in psychiatric symptoms.

Conclusion: We demonstrate that the levels of macrophage migration inhibitory factor decreased after psychotherapeutic interventions in patients with psychiatric disorders. However, this reduction was not associated with an improvement in psychiatric symptoms in response to the treatment. We also found an association between macrophage migration inhibitory factor and its regulating microRNA. However, this association needs to be further examined in future studies.

Keywords: macrophage migration inhibitory factor; MiR-451a; depression; anxiety; stress and adjustment disorders
Introduction

Macrophage migration inhibitory factor (MIF) is one of the first cytokine-like proteins that was discovered more than 50 years ago (B. R. Bloom and Bennett, 1966; David, 1966). MIF was named for its ability to recruit macrophages to sites of inflammation and prevent their random migration. It is synthesized by T- and B-lymphocytes, monocytes, macrophages, dendritic cells, neutrophils, eosinophils, mast cells, and basophils. MIF is widely distributed in tissues. High levels of MIF expression are noted in the endocrine system, especially in the organs that are involved in stress responses, for example, hypothalamus, pituitary, and adrenal glands (Waebner et al., 1997; Calandra and Roger, 2003; Fingerle-Rowson et al., 2003). MIF has pleiotropic effects on inflammation, chemotaxis, cell survival, and proliferation that act as a regulator of innate immune and inflammatory responses (Mitchell et al., 1999; Calandra and Roger, 2003; Bernhagen et al., 2007; Savaskan et al., 2012; J. Bloom and Al-Abed, 2014). Inducers for MIF releasing include microbial products such as lipopolysaccharides and proinflammatory cytokines. Once released, MIF acts in an autocrine or paracrine fashion to induce production of proinflammatory cytokines (Calandra et al., 1994; Calandra, 2003; Calandra and Roger, 2003; J. Bloom and Al-Abed, 2014). MIF also interferes with the antiinflammatory activity of glucocorticoids at a transcriptional and posttranscriptional level (Fingerle-Rowson et al., 2003). Circulating MIF is increased during episodes of inflammation, infection, and stress (Bernhagen et al., 1993; Beishuizen et al., 2001; Calandra and Roger, 2003).

MicroRNAs (miRNAs) are a class of small (21-23-nucleotide), noncoding, single-stranded RNAs that inhibit gene expression by promoting messenger-RNA (mRNA) degradation or inhibiting translation (Ambros, 2004). They influence a variety of physiological cell processes during development and tissue homeostasis by regulating the expression of around 90% of all human genes (Miranda et al., 2006). Numerous miRNAs have been recently detected in several body fluids, including serum, plasma, and cerebrospinal fluid (Weber et al., 2010). Blood cells extensively contact plasma; thus they can be the major contributors to extracellular miRNA content in plasma (Pritchard et al., 2012; Turchinovich et al., 2012; Makarova et al., 2016), which can be derived under different conditions (Turchinovich and Burwinkel, 2012). The biological significance of secreted miRNAs remains to be determined (Turchinovich et al., 2012). One explanation is that cells secrete miRNAs after reducing the target mRNA expression, while the unused miRNA is redundant (Squadrito et al., 2014). On the other hand, the presence of extracellular miRNAs involves cell-to-cell communication via selective miRNA export system (Villarroya-Beltri et al., 2013; Turchinovich et al., 2016; Thomou et al., 2017). Several miRNAs targeting MIF were identified in silico using bioinformatic programs such as TargetScan and miRSystem (version 20120229; and miRDB, version 4.0) (Lu et al., 2012). MIF was identified as a target of miR-451a and this was confirmed by multiple studies. For example, miR-451a can directly target MIF and downregulate its expression and can lead to decreased cell proliferation, colony formation, cell migration and invasion in vitro, suppress xenograft tumor growth in vivo, and modulate epithelial cell survival (Bandres et al., 2009; N. Liu et al., 2013; Graham et al., 2015; Tang et al., 2015; G. Liu et al., 2016). Furthermore, miR-451 is widely expressed in different cells, such as red blood cells, white blood cells, platelet samples, and serum/plasma (K. Wang et al., 2012). However, the relation between circulating miR-451a and MIF is largely unknown.

Disregulation of the immune system and inflammatory response has been linked to the pathophysiology of certain psychiatric disorders, such as depression (Irwin and Miller, 2007). For example, the role of MIF in the pathobiology of depression has been investigated in different ways (J. Bloom and Al-Abed, 2014). MIF is expressed in the brain especially in the areas concerning behavioral symptoms of depression and anxiety (Conboy et al., 2011). Behaviorally, genetic deletion of MIF has resulted in increased anxiety- and depression-like behaviors, and the role of MIF in mediating the antidepressant action of exercise has been found (Conboy et al., 2011; Moon et al., 2012). In blood, the association between MIF and mood disorders may be the opposite. Previous studies have shown that blood MIF levels are increased in subjects with mild to moderate depression, major depression, and other mood disorders (Baugh and Donnelly, 2003; Hawkley et al., 2007; Musil et al., 2011; J. Bloom and Al-Abed, 2014). Treatment with antidepressants can reduce the blood levels of MIF (Cattaneo et al., 2013). MIF does not, however, cross the blood brain barrier (Bacher et al., 2002), so the blood level of MIF may be a consequence of different albeit related processes of depression (J. Bloom and Al-Abed, 2014).

Recently, the role of miRNAs in the development of depression and in antidepressant treatment has gained significant attention. Studies conducted on postmortem brains from subjects who suffered from depression and subsequently committed suicide showed alterations in 29 miRNAs compared with nonpsychiatric control subjects (Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012). Several studies have reported on the role of miR-124-3p in depression. MiR-124-3p may be used as a biomarker for diagnosis and antidepressant treatment response, because miR-124-3p is a target of antidepressants and shows similar changes in the blood and brain of patients suffering with depression (Dwivedi, 2017; Smalheiser et al., 2012).
MIF or miR-451a levels in patients with psychiatric disorders (depression, anxiety, and stress and adjustment disorders) who have been treated in primary health care. Mindfulness-based therapies and CBT are effective ways of treating depressive disorders and are associated with reductions in proinflammatory processes according to previous research (Stephoo et al., 2007; Irwin et al., 2015; Sundquist et al., 2015; Black and Slavich, 2016; Walsh et al., 2016; Memon et al., 2017).

Our study population was based on a previously published randomized controlled trial (RCT) conducted by our research group. The study population included patients with depression, anxiety, stress, or adjustment disorders from 16 primary health care centers in Sweden who were treated with mindfulness-based therapy or TAU. We first investigated the potential changes in plasma levels of MIF and miR-451a after 8 weeks of mindfulness-based therapies or TAU in the patients with depression, anxiety, stress, and adjustment disorders. Later we explored the potential association between plasma levels of MIF and miR-451a at baseline and between changes in levels of MIF and miRNA-451a posttreatment. Finally, we investigated whether the possible changes in MIF and miR-451a were associated with the improvement in psychiatric symptoms (assessed using MADRS-S) posttreatment.

Methods

Study Subjects and Sample Collection

The study population included 168 patients (age 21–65 years) with depression, anxiety, stress, or adjustment disorders. All the patients were recruited from the 16 primary health care centers that had participated in a randomized controlled trial (RCT) of mindfulness therapy compared with TAU, mainly CBT. A detailed description of the study design is provided in a previous article (Sundquist et al., 2015). Patients were recruited between January 4, 2012 and March 22, 2012 at the 16 primary health care centers in the county of Scania (Skåne in Swedish) in southern Sweden. Patients who fulfilled the inclusion criteria were included in the study. All clinical diagnoses were made by doctors at the 16 primary health care centers, including one or more of the following ICD-10 psychiatric diagnoses: F32.0, mild depressive episode; F32.1, moderate depressive episode; F32.9, depressive episode unspecified; F33.0, recurrent depressive disorder, current episode mild; F33.1, recurrent depressive disorder, current episode moderate; F41.0, panic disorder; F41.1, generalized anxiety disorder; F41.2, mixed anxiety disorder; F41.3, other mixed anxiety disorders; F41.8, other specified anxiety disorders; F41.9, anxiety disorder, unspecified; F43.2, adjustment disorders; F43.8, other reactions to severe stress; and F43.9, reaction to severe stress, unspecified; age 20 to 64 years; ability to speak and read Swedish; and a score of ≥10 on the Patient Health Questionnaire (PHQ)-9 or ≥7 on the Hospital Anxiety and Depression Scale (HADS) or a total score on the Montgomery-Åsberg Depression Rating Scale (MADRS-S) between 13 and 34 (mild to moderate depression). The exclusion criteria were as follows: severe personality disorder, risk of suicide, pregnancy, thyroid disease, current psychotherapy of any kind, and participation in any other psychiatric intervention study. Each patient filled in 3 self-rated questionnaires (above-mentioned PHQ-9, HADS-A/HADS-D, and MADRS-S) at baseline and after 8 weeks of follow-up. The patients received antidepressants and tranquillizers (pharmacotherapy) if deemed necessary. Blood samples were collected at the same time as the assessment of self-rated symptoms before and after treatment. Patients with missing clinical information or poor-quality plasma samples, for example, hemolysis samples, were excluded from our study.

Plasma Collection

Whole blood (6 mL) was collected from each participant in EDTA tubes. Blood samples were centrifuged at 2000 g for 10 minutes at 4°C, and the plasma was then aliquoted and stored at -80°C before further processing. Blood samples were processed and the plasma was frozen within 8 hours of collection (Friebe and Volk, 2008).

Detection of MIF and miRNA in Plasma Samples

Plasma MIF levels were determined using the bead-based multiplex assay for the Luminex platform (R&D Systems Inc) based on the manufacturer’s instructions. To summarize, 80 µl of plasma was diluted 1:2 in the dilution buffer and then incubated with antibody-coated magnetic bead. Protein levels were measured using the Bio-Plex suspension array system and data were analyzed with Bio-Plex Manager software (Version 4). Absolute concentrations were calculated from a standard curve generated from 8 serially diluted standards provided in the kit. The intra- and inter assay CV were 3.8% and 4.4%, respectively. Duplicate samples were assayed and all results were reported as means. Plasma miRNA measurement was performed as previously described (X. Wang et al., 2014, 2015). In brief, 50 µL of total RNA was isolated from 200 µL of plasma using the miRNeasy Mini Kit (Qiagen GmbH) according to the manufacturer’s protocol, with minor modifications. miRNAs were reverse transcribed using a Universal cDNA Synthesis kit (Exiqon). Quantitative real-time PCR (qPCR) was carried out in 384-well plates using the CFX384 real-time PCR detection system (Bio-Rad Laboratories). At present, there are different methods to detect hemolysis, including low levels, in plasma/serum (Blondal et al., 2013; Kirschner et al., 2011; Shah et al., 2016). Blondal et al. suggested that the ratio (miR-451a/miR-23a-3p) of red blood cell-enriched miR-451a to miR-23a-3p, the latter not affected by hemolysis, could be used as an indicator of hemolysis. The ratio of miR-451a to miR-23a-3p was found to be the most sensitive method that could detect as little as 0.001% hemolysis in serum. Briefly, miR-451a/miR-23a-3p ratios of <5, 5–7, and >7 indicate low, mild, or high risk of hemolysis. Both miR-451a and miR-23a-3p were measured in all the plasma samples. Samples with a ratio of >7 were excluded in the analysis. Our measurements showed that the Ct value for miR-451a was 23.1 ± 0.8 (mean ± SD) and the Ct value for miR-23a-3p was 26.3 ± 1.4 in all the patient samples. This indicates that miRNA-451a levels displayed little variation between individuals. There were 6% of samples with a ratio of 5 to 7. For these 6% of samples, the Ct value for miR-451a was 22.7 ± 0.7 (mean ± SD) and the Ct value for miR-23a-3p was 28.2 ± 0.9. There were no significant differences in miRNA-451a levels between these 6% of samples and the whole study population. Therefore, we included these 6% in our analysis. At present, no generally accepted standards for normalization of miRNA PCR data have been established. Different methods have been suggested. Some studies have used spike-in oligonucleotides U6 as normalization controls in their study (Zampetaki et al., 2012; Graham et al.,...
Table 1. Characteristics of the Study Population at Baseline (n=168)

| Variables                  | Patients (n=168) |
|----------------------------|------------------|
| Age, y                     |                  |
| Mean (SD)                  | 42.2 (11.0)      |
| Sex, n (%)                 |                  |
| Male                       | 22 (13)          |
| Female                     | 146 (87)         |
| BMI*                       |                  |
| Mean (SD)                  | 26.9 (5.6)       |
| Smoking status, n (%)a     |                  |
| Yes                        | 22 (13.1)        |
| No                         | 143 (85.1)       |
| Alcohol status, n (%)b     |                  |
| Standard size drinks per week |                |
| ≤1                         | 144 (85.7)       |
| >1                         | 19 (11.3)        |
| Antidepressants, n (%)c    |                  |
| Yes                        | 55 (33)          |
| No                         | 97 (58)          |
| Tranquilizers, n (%)d      |                  |
| Yes                        | 24 (14)          |
| No                         | 121 (72)         |
| Baseline MADRS-S           |                  |
| Median score (IQR)         | 20 (10)          |
| Baseline MIF (pg/mL)       |                  |
| Median score (IQR)         | 5398 (4339)      |
| Baseline miR-451a (ΔCt)    |                  |
| Mean (SD)                  | 5.75 (1.30)      |

Abbreviations: BMI, body mass index; IQR, interquartile range.

a9 patients had missing on BMI.
b13 (1.8%) had missing on smoking status.
c5 (3%) had missing on alcohol status.
d16 (9%) had missing on antidepressants.
e23 (14%) had missing on tranquilizers.

Table 2. MIF and miR-451a (ΔCt) for Patients at Baseline and 8-Week Follow-up (Mindfulness and TAU)

| Variables | Baseline | Follow-up | Difference | P-value |
|-----------|----------|-----------|------------|---------|
| MIF       |          |           |            |         |
| Median (IQR) | 5398 (4339) | 4561 (3131) | -718 (2797) | <.0001* |
| miR-451a  |          |           |            |         |
| Mean (SD)  | 5.75 (1.30) | 5.80 (1.32) | 0.05 (1.05) | .54a   |

*Difference tested by Wilcoxon sign-rank test.
bDifference tested by paired t test.

to analyze the changes in MIF/miR-451a and the changes in MADRS-S adjusted for MADRS-S at baseline, both unadjusted and adjusted for the potential confounders (Table 5). This was also examined by testing the potential difference in changes in MIF (using a T-test) between responders (defined as ≥50 % decrease in MADRS-S after follow-up) (Trivedi et al., 2009) and nonresponders (supplementary Table 1). The results from linear regression models for the associations between MADRS-S and MIF and miR-451a levels at both baseline and follow-up are shown in a scatterplot together with a Pearson correlation coefficient (ρ) and a coefficient of determination (R2) (supplementary Figure 3).

A sensitivity analysis was performed where the period between blood collection and isolation of the samples was also considered in the analysis, but it did not change our results (data not shown). Hence, it was not included in the final models.
MiR-451a is enriched in erythrocytes and hemolysis may affect the results. We used a well-known method, the ratio of miR-451a to miR-23a-3p, for detecting hemolysis in plasma/serum. As mentioned in the methods section, samples with a ratio of 7 or more were excluded from the analysis. In total, 6% of the samples with a ratio between 5 and 7 were included in the present study. We also performed an additional analysis where these samples were excluded, but this did not change the results (data not shown).

Statistical analyses were performed by using IBM SPSS Statistics 23 (IBM) and STATA version 14 (StataCorp LP).

### Results

#### Patient Characteristics

The clinical characteristics of the patients are shown in Table 1. The mean age in the whole group (n = 168) was 42.2 years (SD = 11) and most of these participants were women. The mean BMI was 26.9. Most participants were nonsmokers (85.1%) or low consumers of alcohol. The median scores at baseline indicated mild to moderate symptoms of depression and/or anxiety. After treatment, the median scores decreased, indicating none to mild symptoms (similar results for both HADS-A/HADS-D and PHQ-9, data not shown) (Sundquist et al., 2015).

The Effects of Treatment (Mindfulness-Based Therapy or TAU) on Plasma MIF and miR-451a

Table 2 shows that the MIF levels decreased significantly after the 8 weeks of treatment (median: 4561, IQR: 3131, pg/mL) compared with the baseline levels (median: 5398, IQR: 4339, pg/mL) (P < .0001). By contrast, miR-451a levels showed a nonsignificant change. A random-intercept linear regression model was used to examine the potential difference in effect between mindfulness.
and TAU on MIF and mir-451a levels in the patients. This analysis showed no significant difference in patients treated with mindfulness or TAU (data not shown).

The Association Between Plasma MIF and mir-451a in Patients

We further investigated the potential role of mir-451a in regulating MIF levels. Table 3 shows that MIF levels were significantly associated with age and smoking status, with higher age and smoking (yes vs no) associated with higher levels of MIF ($\beta = 0.006, P = .001$ and $\beta = 0.12, P = .03$). Higher BMI and an alcohol consumption of more than one standard size drink were also positively associated to MIF, although not significant. We performed linear regression analysis to assess the potential association between MIF and mir-451a levels at baseline. Unadjusted linear regression revealed that MIF levels at baseline were inversely related to mir-451a levels ($\beta = -0.03, P = .02$). Results remained significant after adjusting for age, sex, BMI, smoking, and alcohol status and pharmacotherapy ($\beta = -0.04, P = .008$).

In addition, we investigated the association between changes (follow-up level minus baseline level) in MIF and mir-451a posttreatment. With the linear regression analysis (as shown in Table 4), we found that the change in levels of MIF was significantly associated with the change in levels of miR-451a ($\beta = -0.08, P < .0001$), although miR-451a showed a nonsignificant change before and after treatment (Table 2). These results are also presented in supplementary Figure 2 ($\rho = -0.40$ and $r^2 = 0.16$). Adjustment for age, sex, BMI, smoking and alcohol status, and pharmacotherapy did not change the results ($\beta = -0.06, P < .0001$).

The Potential Role of MIF/miRNA-451a in the Improvement in Psychiatric Symptoms in Response to the Treatment

Moreover, we performed a linear regression analysis to evaluate the potential association between the changes in MIF/miR-451a and the improvement in psychiatric symptoms in response to the treatment (MADRS-S score). However, there were no significant associations between the change in either MIF or miR-451a and the change in MADRS-S (Table 5). Similar results were found for both HADS-A/HADS-D and PHQ-9 (data not shown in tables). This was also investigated by examining the difference in MIF changes between responders (defined as a percentage reduction of ≥50 % in the MADRS score after follow-up) and nonresponders, with the same conclusion of no significant association (supplementary Table 1). Scatterplots (supplementary Figure 3) were then used to examine potential associations between MIF/miR-451a and MADRS-S (symptoms) at baseline and follow-up separately. A statistically significant but weak association was found only for MIF and MADRS-S at follow-up ($\rho = -0.17; R^2 = 0.03$).

Discussion

This is, to our knowledge, the first study to explore the potential role of plasma MIF and mir-451a in patients with depression, anxiety, or stress and adjustment disorders treated with mindfulness-based therapy or TAU. Our main findings were the following: (1) the levels of MIF were significantly decreased after 8 weeks of treatment in patients, whereas mir-451a levels showed a nonsignificant change; (2) a significant association was found between levels of MIF and mir-451a in patients at baseline as well as between changes in MIF and changes in mir-451a post-treatment; (3) no significant associations were found between the changes in either MIF or mir-451a and improvement of psychiatric symptoms.

It is of note that mindfulness-based therapy or TAU in our study reduced MIF levels. MIF is important in the homeostasis of the host immune response. MIF has been reported to be involved in the pathobiology of depression/anxiety (Musil et al., 2011; J. Bloom and Al-Abed, 2014). Edwards et al. reported that elevated MIF related to depressive symptoms, a smaller cortisol reactivity to acute stress, and lowered morning cortisol values, indicating that MIF may act as a neuro-immune mediator linking depressive symptoms with inflammation and hypothalamic–pituitary–adrenal axis dysregulation (Edwards et al., 2010). A previous study also showed that MIF levels were reduced after treatment with antidepressants in patients with depression (Cattaneo et al., 2013). However, it is not known whether mindfulness-based therapy or CBT have effect on MIF levels. In the present study, we found that MIF was significantly decreased after psychotherapeutic interventions. In line with our finding, Walsh et al. reported that a 4-week mindfulness-based intervention can reduce salivary IL-6 and TNF-α in women with depressive symptomatology (Walsh et al., 2016). Furthermore, Moreira et al. found that CBT significantly decreases the serum levels of IL-6 and TNF-α in patients with depressive symptoms (Moreira et al., 2015). Based on the evidence above, mindfulness treatment/CTB may also seem to have an effect on inflammatory immune response in depression, but the underlying mechanism is not well established.

There is not sufficient evidence to show that pharmacological antidepressive treatment affects the mir-451a expression. We found only one study showing that treatment with antidepressants could reverse the stress-induced change of mir-451a expression in rat hippocampus. However, it is not known whether psychotherapeutic interventions can affect plasma levels of MIF or mir-451a in patients with psychiatric disorders. In the present study, we found a nonsignificant change in mir-451a after the treatment. We were unable to identify the exact mechanism behind this however, as most miRNAs regulate their targets at cellular levels. We have quantified the circulating miRNA that may not represent the whole effect of regulation by this miRNA at the cellular level; small changes in the circulating mir-451a may represent large changes in cellular mir-451a levels.

It is well known that mir-451a can directly target MIF and downregulate its expression in the cells (Bandres et al., 2009; N. Liu et al., 2013). The circulating mir-451a is usually secreted from their cells of origin (Arroyo et al., 2011; Valadi et al., 2007). However, the relation between circulating MIF and mir-451a has never been reported. In the present study, we found that there is a significant inverse association between plasma levels of MIF and mir-451 levels in patients with psychiatric disorders. Our study is the first to evaluate a possible association of MIF with circulating miRNA in patients with psychiatric disorders. Similarly, a recently published study reported another circulating miRNA (mir-939) regulates multiple proinflammatory genes in other disease also (McDonald et al., 2016). We also in this study show a significant association between the change in MIF levels and the change in mir-451a levels in patients with psychiatric disorders after psychotherapeutic interventions. However, the biological mechanism behind this relationship still needs to be examined. Therefore, in any future studies, it will be of interest to examine the relationship between MIF and mir-451a at cellular level in patients with depression, anxiety, and stress and adjustment disorders (Cattaneo et al., 2016) (McDonald et al., 2016).
We have previously shown that mindfulness therapy and TAU reduced psychiatric symptoms in patients with depression, anxiety, and stress and adjustment disorders (Sundquist et al., 2015). Therefore, we investigated whether the changes in MIF and miR-451a were associated with the improvement in psychiatric symptoms in response to psychotherapeutic interventions. However, we were unable to detect any significant associations between response and MIF or miR-451a. In agreement with our findings, a recent study reported that a mindfulness-based intervention can reduce salivary cytokines although the reduction was not related to the improvement in depressive symptoms (Walsh et al., 2016). Cattaneo et al also reported that treatment with antidepressants reduced the levels of MIF, but the reduction was not associated with treatment response (Cattaneo et al., 2013). Recent evidence shows that the expression levels of proinflammatory and inflammatory cytokines in postmortem brain have a positive relationship with the levels in plasma in patients with depression (Pandey et al., 2012; Miller and Raison, 2016). However, it is important to note that MIF does not cross the blood brain barrier (Bacher et al., 2002; J. Bloom and Al-Abed, 2014). Therefore, the changes in MIF in the plasma may differ from the changes in the brain. Furthermore, multiple preinflammatory cytokines are involved in the development of depression. It is possible that elevated levels of some of these inflammatory cytokines may not be the consequence of the depression but could be a result of brain dysfunction associated with depression and therefore may not be associated with response to treatment. Therefore, a simple reduction in MIF levels may not be enough to improve the depressive symptoms in response to mindfulness therapy or TAU. Taken together, MIF may not act as an independent predictive biomarker for mindfulness therapy or TAU in the circulation.

Our study has several strengths. We provide evidence that psychotherapeutic interventions may reduce MIF levels in patients with psychiatric disorders. MIF levels and miR-451a levels at baseline as well as changes in levels posttreatment were significantly associated with each other. These findings suggest that miRNA may interact with the inflammatory process linked to the psychotherapeutic interventions in patients with psychiatric disorders. As such, this novel contribution has never been shown in previous studies. Although our findings are promising, several general limitations should be considered. First, we do not have postmortem samples to further confirm our findings. Second, the blood samples used for the assays were frozen between 4 to 8 hours after collection, which may affect our results. However, according to Friebe et al., the cytokine levels in EDTA tubes are not affected if the samples are prepared within 8 hours at room temperature (Friebe and Volk, 2008). The time points for both blood collection and plasma isolation were, however, available in our patient samples; the results were adjusted for this time point and the results were not affected. Third, we did not perform separate analyses according to the subtype of psychiatric disorders. However, overlapping symptoms are relatively common among these conditions and the patients were therefore analyzed together. Fourth, our findings cannot be used to guide clinical practice methods at present; it needs to be confirmed in independent cohorts. Moreover, our study did not include patients that did not receive any therapy as a control. It might be possible that the changes in MIF and miR-451a were simply a reflection of variability over time.

In conclusion, our results suggest that 8 weeks of psychotherapeutic interventions can reduce the MIF levels in patients with psychiatric disorders. However, this reduction was not associated with an improvement in psychiatric symptoms in response to the treatment. The association between plasma levels of MIF and miR-451 may relate to the regulatory process occurring at the cellular level, even though the biological mechanisms need to be examined in future studies.

Supplementary Material

Supplementary data are available at International Journal of Neuropsychopharmacology online.

Acknowledgments

This project was supported by the Swedish Research Council (2012–2378 and 2014–10134) and FORTE to Jan Sundquist, the Swedish Research Council (2014–2517) and FORTE to Kristina Sundquist, as well as ALF funding from Region Skåne awarded to Jan Sundquist and Kristina Sundquist. We would like to thank science editor Patrick Reilly for critical reading of the manuscript as well as to biomedical analyst Hamideh Rastkhani for support in the laboratory.

Statement of Interest

None.

References

Ambros V (2004) The functions of animal microRNAs. Nature 431:350–355.
Arroyo JD, Chevillet JR, Kroh EM, Ruf IK, Pritchard CC, Gibson DF, Mitchell PS, Bennett CF, Pogosova-Agadjanyan EL, Stirewalt DL, Tait JF, Tewari M (2011) Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci U S A 108:5003–5008.
Bacher M, Weihe E, Dietzschold B, Meinhardt A, Vedder H, Gemsa D, Bette M (2002) Borna disease virus-induced accumulation of macrophage migration inhibitory factor in rat brain astrocytes is associated with inhibition of macrophage infiltration. Glia 37:291–306.
Bandres E, Bitarte N, Arias F, Agorreta J, Fortes P, Agirre X, Zarate R, Diaz-Gonzalez JA, Ramirez N, Sola JJ, Jimenez P, Rodriguez J, Garcia-Foncillas J (2009) MicroRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clin Cancer Res 15:2281–2290.
Baugh JA, Donnelly SC (2003) Macrophage migration inhibitory factor: a neuroendocrine modulator of chronic inflammation. J Endocrinol 179:15–23.
Beishuizen A, Thijs LG, Haanen C, Vermes I (2001) Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. J Clin Endocrinol Metab 86:2811–2816.
Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, Manogue KR, Cerami A, Bucala R (1993) MIF is a pituitary-derived cytokine that potentiates lethal endotoxemia. Nature 365:756–759.
Bernhagen J, Krohn R, Lue H, Gregory JL, Zernecke A, Koenen RR, Dewor M, Georgiev I, Schober A, Leng L, Kooistra T, Fingerle-Rowson G, Ghezzi P, Kleemann R, McColl SR, Bucala R, Hickey MJ, Weber C (2007) MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat Med 13:587–596.
Black DS, Slavich GM (2016) Mindfulness meditation and the immune system: a systematic review of randomized controlled trials. Ann N Y Acad Sci 1373:13–24.
Blondal T, Jensby Nielsen S, Baker A,Andreassen D, Mouritzen P, Wrang Teilm M, Dahlsvleen IK (2013) Assessing sample and mirna profile quality in serum and plasma or other biofluids. Methods 59:S1–S6.
Bloom BR, Bennett B (1966) Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153:80–82.
Bloom J, Al-Abed Y (2014) MIF: mood improving/inhibiting factor? J Neuroinflammation 11:11.
Bye A, Røsjø H, Aspenes ST, Condorelli G, Omland T, Wisløff U (2013) Circulating microRNAs and aerobic fitness—the HUNT-study. Plos One 8:e57496.
Calandra T (2003) Macrophage migration inhibitory factor and host innate immune responses to microbes. Scand J Infect Dis 35:573–576.
Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800.
Calandra T, Bernhagen J, Mitchell RA, Bucala R (1994) The macrophage is an important and previously unrecognized source of macrophage migration inhibition factor. J Exp Med 179:1895–1902.
Camkurt MA, Acar S, Çoykun S, Güneş M, Güneş Y, Yılmaz MF, Görür A, Tamer L (2015) Comparison of plasma microRNA levels in drug naive, first episode depressed patients and healthy controls. J Psychiatr Res 69:67–71.
Cattaneo A, Gennarelli M, Uher R, Breen G, Farmer A, Aitchison KJ, Craig IW, Anacker C, Zunsztain PA, McGuffin P, Pariante CM (2013) Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology 38:377–385.
Cattaneo A, Ferrari C, Uher R, Bocchio-Chiavetto L, Riva MA, Pariante CM (2016) Absolute measurements of macrophage migration inhibitory factor and interleukin-1-beta mRNA levels accurately predict treatment response in depressed patients. J Neuropsychopharmacol 19.
Chen L, Jin Y, Wang L, Sun F, Yang X, Shi M, Zhan C, Shi Y, Wang Q (2017) Identification of reference genes and mirnas for qrt-PCR in human esophageal squamous cell carcinoma. Med Oncol 34:2.
Conboy I, Varea E, Castro JE, Sakouhi-Ouertatani H, Calandra T, Lashuel HA, Sandi C (2011) Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol Psychiatry 16:533–547.
David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 56:72–77.
Dwivedi Y (2017) MicroRNA-124: a putative therapeutic target and biomarker for major depression. Expert Opin Ther Targets 21:653–656.
Edwards KM, Bosch JA, Engelnd CG, Cacioppo JT, Marucha PT (2010) Elevated macrophage migration inhibitory factor (MIF) is associated with depressive symptoms, blunted cortisol reactivity to acute stress, and lowered morning cortisol. Brain Behav Immun 24:1202–1208.
Friebe A, Volk HD (2008) Stability of tumor necrosis factor alpha, interleukin 6, and interleukin 8 in blood samples of patients with systemic immune activation. Arch Pathol Lab Med 132:1802–1806.
Graham A, Falcone T, Nothnick WB (2015) The expression of microRNA-451 in human endometriotic lesions is inversely related to that of macrophage migration inhibitory factor (MIF) and regulates MIF expression and modulation of epithelial cell survival. Hum Reprod 30:642–652.
Hawkley LC, Bosch JA, Engelnd CG, Marucha PT, Cacioppo JT (2007) Loneliness, dysphoria, stress and immunity: a role for cytokines. Cytokine Stress Immun 67–85.
Irwin MR, Miller AH (2007) Depressive disorders and immunity: 20 years of progress and discovery. Brain Behav Immun 21:374–383.
Irwin MR, Olmstead R, Breen EC, Witarama T, Carrillo C, Sadeghi N, Arevalo JM, Ma J, Nicassio P, Boatzin R, Cole S (2015) Cognitive behavioral therapy and tai chi reverse cellular and genomic markers of inflammation in late-life insomnia: a randomized controlled trial. Biol Psychiatry 78:721–729.
Issler O, Haramati S, Paul ED, Navon I, Zhawg R, Gil S, Mayberg HS, Dunlop BW, Menke A, Awatramani R, Bender EB, Deneris ES, Lowry CA, Chen A (2014) MicroRNA 135 is essential for chronic stress resiliency, antidepressant efficacy, and intact serotoninergic activity. Neuron 83:344–360.
Kirschen MB, Kao SC, Edelman JJ, Armstrong NJ, Valley MF, van Zandwijk N, Reid G (2011) Haemolysis during sample preparation alters microRNA content of plasma. Plos One 6:e24145.
Liu G, Xu Z, Hao D (2016) MicroRNA-451 inhibits neuroblastoma proliferation, invasion and migration by targeting macrophage migration inhibitory factor. Mol Med Rep 13:2253–2260.
Liu N, Jiang N, Guo R, Jiang W, He QM, Xu YF, Li YQ, Tang LL, Mao YP, Sun Y, Ma J (2013) Mir-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma. Mol Cancer 12:123.
Lu TP, Lai CW, Tsai MH, Chiu YC, Hsiao CK, Lai LC, Chuang EY (2012) MiRSystem: an integrated system for characterizing enriched functions and pathways of microRNA targets. Plos One 7:e42390.
Makarova JA, Shkurnikov MU, Wicklein D, Lange T, Samatov TR, Turchinovich AA, Tsetenitsky AG (2016) Intracellular and extracellular microRNA: an update on localization and biological role. PLoS Histochem Cytochem 51:33–49.
McDonald MK, Ramanathan S, Touati A, Zhou Y, Thanawala RU, Alexander GM, Sacan A, Ajit SK (2016) Regulation of proinflammatory genes by the circulating microRNA hsa-mir-939. Sci Rep 6:30976.
Memon AA, Sundquist K, Ahmad A, Wang X, Hedelius A, Sundquist J (2017) Role of IL-8, CRP and epidermal growth factor in depression and anxiety patients treated with mindfulness-based therapy or cognitive behavioral therapy in primary health care. Psychiatry Res 254:311–316.
Miller AH, Raison CL (2016) The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 16:22–34.
Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B, Rigoutsos I (2006) A pattern-based method for the identification of microRNA binding sites and their corresponding heteroduplexes. Cell 126:1203–1217.
Mitchell RA, Metzen, Peng T, Bucala R (1999) Sustained mitogen-activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274:18100–18106.
Moon HY, Kim SH, Yang YR, Song P, Yu HS, Park HG, Hwang O, Lee-Kwon W, Seo JK, Hwang D, Choi JH, Bucula R, Ryu SH, Kim YS, Suh PG (2012) Macrophage migration inhibitory factor mediates the antidepressant actions of voluntary exercise. Proc Natl Acad Sci U S A 109:13094–13099.

Moreira FP, Cardoso Tde A, Mondin TC, Souza LD, Silva R, Jansen K, Osse JP, Wiener CD (2015) The effect of proinflammatory cytokines in cognitive behavioral therapy. J Neuroimmunol 285:143–146.

Musil R, Schwarz MJ, Riedel M, Dehning S, Cerovecki A, Spellmann I, Arolt V, Müller N (2011) Elevated macrophage migration inhibitory factor and decreased transforming growth factor-beta levels in major depression–no influence of celecoxib treatment. J Affect Disord 134:217–225.

O’Connor RM, Grenham S, Dinan TG, Cryan JF (2013) MicroRNAs as novel antidepressant targets: converging effects of keta-mine and electroconvulsive shock therapy in the rat hippocampus. Int J Neuropsychopharmacol 16:1885–1892.

Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, Conley RR, Dwivedi Y (2012) Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 46:57–63.

Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M (2012) Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prev Res (Phila) 5:492–497.

Roy B, Dunbar M, Shelton RC, Dwivedi Y (2017) Identification of microRNA-124-3p as a putative epigenetic signature of major depressive disorder. Neuropsychopharmacology 42:864–875.

Savaskan NE, Fingerle-Rowson G, Buchfelder M, Eyüpoglu IY (2012) Brain miffed by macrophage migration inhibitory factor. Int J Cell Biol 2012:139573.

Shah JS, Soon PS, Marsh DJ (2016) Comparison of methodologies to detect low levels of hemolysis in serum for accurate assessment of serum microRNAs. Plos One 11:e0153200.

Smallheiser NR, Lugli G, Rizavi HS, Torvik VI, Turecki G, Dwivedi Y (2012) MicroRNA expression is down-regulated and reorganized in the prefrontal cortex of depressed suicide subjects. Plos One 7:e33201.

Song J, Bai Z, Han W, Zhang J, Meng H, Bi J, Ma X, Han S, Zhang Z (2012) Identification of suitable reference genes for qpcr analysis of serum microRNA in gastric cancer patients. Dig Dis Sci 57:897–904.

Squadrito ML, Baer C, Burdet F, Maderna C, Gilfillan GD, Lyle R, Jberson M, De Palma M (2014) Endogenous mRNAs modulate microRNA sorting to exosomes and transfer to acceptor cells. Cell Rep 8:1432–1446.

Steptoe A, Hamer M, Chida Y (2007) The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun 21:901–912.

Sundquist J (2015) Mindfulness group therapy in primary care a review and meta-analysis. Brain Behav Immun 21:901–912.

Villarroya-Beltri C, Gutiérrez-Vázquez C, Sánchez-Cabo F, Pérez hernández D, Vázquez J, Martín-Cofres N, Martinez-Herrera DJ, Pascual-Montano A, Mittelbrunn M, Sánchez-Madrid F (2013) Sumoylated hnrnpa2b1 controls the sorting of microRNAs into exosomes through binding to specific motifs. Nat Commun 4:2980.

Walsh E, Eisenlohr-Moul T, Baer R (2016) Brief mindfulness training reduces salivary IL-6 and TNF-α in young women with depressive symptomatology. J Consult Clin Psychol 84:887–897.

Wan Y, Liu Y, Wang X, Wu J, Liu K, Zhou J, Liu L, Zhang C (2015) Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. Plos One 10:e0121975.

Wang K, Yuan Y, Cho JH, McClarty S, Baxter D, Galas DJ (2012) Comparing the microRNA spectrum between serum and plasma. Plos One 7:e41561.

Wang X, Sundquist K, Hedelius A, Palmér K, Memon AA, Sundquist J (2015) Circulating microRNA-144-5p is associated with depressive disorders. Clin Epigenetics 7:69.

Wang X, Sundquist J, Zöller B, Memon AA, Palmér K, Sundquist K, Bennet L (2014) Determination of 14 circulating microRNAs in swedes and Iraqis with and without diabetes mellitus type 2. Plos One 9:e86792.

Wang X, Sundquist K, Elf JL, Strandberg K, Svensson PJ, Hedelius A, Palmer K, Memon AA, Sundquist J, Zöller B (2016) Diagnostic potential of plasma microRNA signatures in patients with deep-vein thrombosis. Thromb Haemost 116:328–336.

Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56:1733–1741.

Zampetaki A, Willeit P, Tilling I, Drozdov I, Prokopi M, Renard JM, Mayr A, Weger S, Schett G, Shah A, Boulanger CM, Willeit J, Chowienczyk Pj, Kiechel S, Mayr M (2012) Prospective study on circulating microRNAs and risk of myocardial infarction. J Am Coll Cardiol 60:290–299.